A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resistant patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer
- Conditions
- Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include young age, cell type other than clear cell or mucinous, lower stage, good performance status, small residual tumor volume after surgery, and absence of ascites. The prognosis of patients with resistant / refractory ovarian cancer is uniformly poor with median overall survival ranging from 35 – 41 weeks.
- Registration Number
- EUCTR2004-005181-20-HU
- Lead Sponsor
- ovartis Pharma Services AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Female
- Target Recruitment
- 810
- Histologically confirmed diagnosis of epithelial ovarian, primary fallopian or primary peritoneal cancer.
- No more than one prior taxane/platinum-based combination chemotherapy regimen at the initial platinum dose of carboplatin AUC 5-6 or cisplatin 75mg/m2
- Taxane/platinum refractory/resistant patients must present with either measurable (by RECIST criteria) or non-measurable (CA-125 by Rustin criteria) progressive disease
- Left ventricular ejection fraction (LVEF) >/= 50% by MUGA or 2-D echocardiography
- Age > 18 years.
- WHO performance status of 0, 1, or 2.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
- Patients with CA-125-only disease
- Unresolved bowel obstruction
- Prior administration of and/or known hypersensitivity to: epothilones, anthracyclines and/or pegylated liposomal doxorubicin
- Any peripheral neuropathy > CTC grade 1
- Unresolved diarrhea of any grade within last 7 days prior to start of treatment.
- Presenting with leptomeningeal involvement
- Within 3 weeks of receiving any prior chemotherapy or radiotherapy or who are planning to receive either while participating in the study
- Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease
- History of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer or cervical cancer in situ
- Receiving hematopoietic growth factors (except erythropoietin)
- Concomitant administration of Coumadin® or other agents containing warfarin
- Concomitant administration of any drug/agent known to cause, or increase the severity of, diarrhea
Concomitant administration of any drug/agent known to interact negatively with doxorubicin or pegylated liposomal doxorubicin
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method